Sionna Therapeutics (SION) Liabilities and Shareholders Equity (2024 - 2026)

Sionna Therapeutics (SION) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $305.0 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 17.48% year-over-year to $305.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 138.07% YoY), and the FY2025 full-year result was $326.0 million, up 75.48% from the prior year.
• Liabilities and Shareholders Equity slipped to $305.0 million in Q1 2026, from $326.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $369.7 million in Q1 2025 to a low of $185.8 million in Q4 2024.
• A 3-year average of $313.0 million and a median of $332.6 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 75.48% in 2025 and retreated 17.48% in 2026, its largest moves.
• Tracing SION's Liabilities and Shareholders Equity over 3 years: stood at $185.8 million in 2024, then soared by 75.48% to $326.0 million in 2025, then retreated by 6.42% to $305.0 million in 2026.
• Business Quant data shows SION's Liabilities and Shareholders Equity at $305.0 million in Q1 2026, $326.0 million in Q4 2025, and $339.3 million in Q3 2025.